



SAFETY DATA SHEET

Title: JURAMATE INJECTION		Document: SDS-AU043	
		Rev: 3.1	PAGE 1 OF 8
Status: Current	Issue Date: 20-Feb-2023	Effective Date: 01-Mar-2023	Review Date: 17-Jan-2028

Section 1: IDENTIFICATION of CHEMICAL PRODUCT and COMPANY

Product Name:	Juramate Synthetic Prostaglandin for Cattle and Horses Juramate Prostaglandin Injection Juramate P Prostaglandin Injection for Pigs
Product Identifier:	A 250 µg/mL cloprostenol (as the sodium salt) solution for injection (Juramate Synthetic Prostaglandin for Cattle and Horses and Juramate Prostaglandin Injection). A 87.5 µg/mL cloprostenol (as the sodium salt) solution for injection (Juramate P Prostaglandin Injection for Pigs)
Recommended Use:	A luteolytic agent for use in horses and cattle (Juramate Synthetic Prostaglandin for Cattle and Horses and Juramate Prostaglandin Injection). For the induction of farrowing in sows and gilts (Juramate P Prostaglandin Injection for Pigs).
Restrictions on Use:	For animal treatment only.
Company Identification:	Jurox Pty Limited (part of Zoetis)
Address:	85 Gardiner Street, Rutherford, NSW 2320, Australia
Email:	customerservice@jurox.com.au
Customer Service:	1800 022 442 (Mon-Fri, 8:00am - 6:00pm AEST)
National Poisons Information Centre:	13 11 26 (24 hours)
Emergency Telephone Number:	1800 814 883 (all hours)

Section 2: HAZARDS IDENTIFICATION

GHS Hazard Classifications: This product has been assessed according to GHS and is classified as follows:

GHS Category	Hazard code	Hazard Statement
Reproductive Toxicant Category 1	H360	May damage fertility or the unborn child.

Signal word: DANGER

GHS Pictograms:



Health hazard

Precautionary statements:

General

P101

If medical advice is needed, have product container or label at hand.

P102

Keep out of reach of children.



SAFETY DATA SHEET

Title: JURAMATE INJECTION		Document: SDS-AU043	
		Rev: 3.1	PAGE 2 OF 8
Status: Current	Issue Date: 20-Feb-2023	Effective Date: 01-Mar-2023	Review Date: 17-Jan-2028

Prevention

P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves, eye protection / face protection.

Response

P308+P313 IF exposed or concerned: Get medical advice/attention.

Storage

P405 Store locked up.

Disposal

P501 Dispose of unused product in accordance with local regulations. Dispose of empty container by wrapping with paper and placing in garbage.

N.B.: The above statements are determined by Work Health and Safety regulations and may not reflect Signal Headings and First Aid and Safety statements on product labelling, which are determined by a competent authority during assessment for registration.

Other hazards: None known

Section 3: COMPOSITION / INFORMATION on INGREDIENTS

INGREDIENT	CAS No.	CONTENT
Cloprostenol sodium	55028-72-3	0.00875% (Juramate P Prostaglandin Injection for Pigs) 0.0263% (Juramate Synthetic Prostaglandin for Cattle and Horses and Juramate Prostaglandin Injection)
Ingredients not contributing to the hazards	-	> 99%

Section 4: FIRST AID MEASURES

General Information: Consult the National Poisons Centre on 13 11 26 or a doctor immediately in every case of suspected chemical poisoning. Never give fluids or induce vomiting if a patient is unconscious or convulsing regardless of cause of injury. If medical advice/attention is needed, have this SDS, product container or label at hand.

Symptoms and Effects of Exposure: Cloprostenol is readily absorbed through the skin and may cause abortion or bronchospasm.

Inhalation: If fumes or combustion products are inhaled remove from contaminated area. Other measures are usually unnecessary. If respiratory symptoms occur, remove patient to fresh air. Lay patient down and keep warm and rested. If breathing is shallow or has stopped, ensure airway is clear and apply resuscitation. If breathing is difficult, give oxygen and seek medical assistance immediately.

Ingestion: If swallowed do NOT induce vomiting. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. If vomiting occurs, Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Call a POISON CENTER/doctor if you feel unwell.



SAFETY DATA SHEET

Title: JURAMATE INJECTION		Document: SDS-AU043	
		Rev: 3.1	PAGE 3 OF 8
Status: Current	Issue Date: 20-Feb-2023	Effective Date: 01-Mar-2023	Review Date: 17-Jan-2028

Skin: If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation. Cloprostenol is readily absorbed through the skin and may cause abortion or bronchospasm.

Eye: If eye contact occurs: Immediately flush the eye continuously with running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Continue flushing for at least 20 minutes. If eye irritation persists, get medical advice/attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.

Injection: Treat as for needle stick injury. Wash the wound thoroughly with soap and water or use a waterless cleanser or antiseptic if water is unavailable. Apply a dressing as necessary and apply pressure through the dressing if bleeding is still occurring. Do not squeeze or rub the injury site. Dispose of the needle in a suitable sharps container and, seek medical advice/attention immediately especially if pregnant or an asthmatic.

Recommended First Aid Facilities: Ready access to running water and soap is required. Accessible eyewash is required.

Advice to Doctor: Contains cloprostenol sodium, a synthetic prostaglandin F_{2α} drug. The drug is a potent luteolytic agent and abortifacient and may cause bronchospasm. Should respiratory embarrassment occur, a rapid acting bronchodilator such as isoprenaline or salbutamol by inhalation is required.

Section 5: FIRE FIGHTING MEASURES

Flash Point: Not flammable. Not combustible. Not considered to be a significant fire risk.

Hazardous Combustion Products: If involved in a fire, may emit poisonous and corrosive fumes.

Extinguishing Media: There is no restriction on the type of extinguisher which may be used. Use extinguishing media suitable for surrounding area.

Protective Equipment: Protective gloves and boots and breathing apparatus.

HAZCHEM Code: None specified.

Section 6: ACCIDENTAL RELEASE MEASURES

Spills and Disposal: Wear gloves and appropriate protective clothing. Avoid breathing vapours and contact with skin and eyes. Clean up all spills immediately. For small spills, clean up spilled product then wipe area and put empty container in garbage. For large spills, exclude non-essential personnel from the area. Contain and absorb spill with sand, earth, inert material or vermiculite. Prevent spillage from entering drains or water courses and call emergency services. Stop leak if safe to do so.

Protective Clothing: For appropriate personal protective equipment see section 8.

Environmental Precautions: Prevent from entering drains, waterways or sewers. If spill does enter waterways contact local authority.

Section 7: HANDLING AND STORAGE

WARNING: ASTHMATICS AND WOMEN OF CHILD-BEARING AGE AVOID CONTACT WITH PRODUCT.



SAFETY DATA SHEET

Title: JURAMATE INJECTION		Document: SDS-AU043	
		Rev: 3.1	PAGE 4 OF 8
Status: Current	Issue Date: 20-Feb-2023	Effective Date: 01-Mar-2023	Review Date: 17-Jan-2028

Handling: This product is a Scheduled Poison (S4) and therefore must be stored and maintained in accordance with the relevant State Poisons Act. Handle this product with care to avoid exposure, taking all recommended precautions. Avoid accidental self-injection. Avoid contact with skin, eyes and inhalation of vapours. Use in a well-ventilated area. Do not allow clothing wet with material to stay in contact with skin. Use personal protective equipment as required. Do not eat, drink or smoke while handling product. Wash hands after use.

Storage: Keep out of reach of children. Store below 30°C (room temperature). Protect from light. Store in a cool, dry, well-ventilated area. Store in original containers, securely sealed, away from foodstuffs. Store locked up and protect containers against physical damage. DO NOT re-use the container.

Other Information: Avoid contact with incompatible substances as listed in Section 10. Always read the label before use. See label for further information on handling and storage.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

This SDS describes personal protective measures relating to long term industrial and manufacturing exposure and emergency situations, such as accidents and spills. See product label for personal protective measures during normal use of the marketed product.

Exposure Limits: An exposure limit for the mixture has not been established. No exposure standards for the ingredients are available.

Engineering Controls: Handle in a well-ventilated area. Ensure that the work environment remains clean.

Personal Protective Equipment (PPE):

Eye protection: Safety glasses with side shields or chemical goggles are recommended when handling bulk quantities of this product.

Skin protection: When handling bulk quantities, prevent skin contact by wearing chemical protective gloves e.g. PVC. Wear safety footwear or safety gumboots, e.g. rubber.

Respiratory protection: Not required for the normal use of this product.

Other: When handling bulk quantities of this product, overalls, PVC apron, barrier cream, skin cleansing cream and eye wash unit may be required.



SAFETY DATA SHEET

Title: JURAMATE INJECTION		Document: SDS-AU043	
		Rev: 3.1	PAGE 5 OF 8
Status: Current	Issue Date: 20-Feb-2023	Effective Date: 01-Mar-2023	Review Date: 17-Jan-2028

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

Appearance:	Clear colourless liquid	Lower flammability limits:	Not available
Odour:	Not available	Vapour Pressure:	Not available
Odour threshold:	Not available	Vapour density:	Not available
pH:	5.6 – 6.1	Relative density:	Not applicable
Melting Point:	Not applicable	Specific Gravity:	Not available
Boiling Point:	Not available	Solubility in Water:	Soluble
Flash Point:	Not available	Partition coefficient:	Not available
Evaporation Rate:	Not available	Auto-ignition temperature:	Not available
Flammability:	Not flammable	Decomposition temperature:	Not available
Upper flammability limits:	Not available	Viscosity:	Not applicable

Section 10: STABILITY AND REACTIVITY

Reactivity: This product is unlikely to react or polymerise under normal storage conditions.

Chemical Stability: When stored appropriately this product should show no significant degradation within the expiry period shown on the label.

Conditions to Avoid: Extreme temperatures.

Incompatible Materials: Oxidising agents.

Hazardous Decomposition Products: Decomposes on heating and may produce toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other pyrolysis products typical of burning organic material.

Section 11: TOXICOLOGICAL INFORMATION

REMARK: Prostaglandins of the F_{2α} type such as cloprostenol may cause bronchospasm, and induction of labour or abortion in pregnant women if accidentally administered. Biological activities of prostaglandins include smooth muscle stimulation, dilation of arterioles, bronchial dilation, lowering of blood pressure, increase in ocular pressure and inhibition of gastric secretions.

Acute Toxicity:

Ingestion: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be acutely toxic by the oral route. However, ingestion of this material may be harmful to the health of the individual.

Cloprostenol sodium: Oral LD₅₀: >25 mg/kg (rat).

Inhalation: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be acutely toxic by the inhalation route. Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.

Cloprostenol sodium: No data.



SAFETY DATA SHEET

Title: JURAMATE INJECTION		Document: SDS-AU043	
		Rev: 3.1	PAGE 6 OF 8
Status: Current	Issue Date: 20-Feb-2023	Effective Date: 01-Mar-2023	Review Date: 17-Jan-2028

Dermal: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be acutely toxic by the dermal route. Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting. Entry into the bloodstream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

Cloprostenol sodium: No data.

Injection: No data for the mixture is available. Effects will vary in severity according to the quantity involved, from localised site reaction (pain, redness, swelling) to acute allergic reaction.

Skin Corrosion / Irritation: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a skin irritant. Cloprostenol is readily absorbed through the skin and may cause abortion or bronchospasm.

Serious Eye Irritation: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be an eye irritant.

Respiratory or Skin Sensitisation: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a skin sensitizer. Cloprostenol is readily absorbed through the skin and may cause abortion or bronchospasm.

Germ Cell Mutagenicity: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a germ cell mutagen.

Carcinogenicity: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be carcinogenic.

Reproductive Toxicity: No data for the mixture is available. Based on available data for the ingredients, the mixture has a classification of **Reproductive Toxicity Category 1**. Cloprostenol has the potential to induce premature labour or abortion. Overexposure may cause foetal harm. Females of childbearing potential should avoid the product. Ample evidence exists from experimentation that reduced human fertility is directly caused by exposure to prostaglandins.

STOT: Single exposure: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a Specific Target Organ Toxicant after single exposure.

STOT: Repeat exposure: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a Specific Target Organ Toxicant after repeat exposure.

Aspiration Hazard: No data available.

Narcotic Effects: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to have any narcotic effects.

Section 12: ECOLOGICAL INFORMATION

Ecotoxicity: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be an ecological toxicant.



SAFETY DATA SHEET

Title: JURAMATE INJECTION		Document: SDS-AU043	
		Rev: 3.1	PAGE 7 OF 8
Status: Current	Issue Date: 20-Feb-2023	Effective Date: 01-Mar-2023	Review Date: 17-Jan-2028

Section 13: DISPOSAL INFORMATION

Product Disposal: Dispose of product only by using according to label or at an approved landfill.

Container Disposal: Dispose of container by wrapping with paper and placing in the garbage.

Section 14: TRANSPORT INFORMATION

Dangerous Goods Classification: Not classified as a Dangerous Good for land, sea or air transport.

Section 15: REGULATORY INFORMATION

Poison Schedule (SUSMP): S4

APVMA No.: 48725 (Juramate Synthetic Prostaglandin for Cattle and Horses);
64183 (Juramate Prostaglandin Injection).

AICS: All of the significant ingredients in this formulation are compliant with NICNAS regulations.

Section 16: OTHER INFORMATION

This information is based on data believed by Jurox Pty Limited to be accurate at the time of writing but is subject to change without notice. It is given in good faith, but no warranty expressed or implied is made as to its accuracy, completeness otherwise and no assumption of liability from howsoever arising is made by Jurox Pty Limited by reason of the provision of this information. Every person dealing with the materials referred to herein does so at his/her own risk absolutely and must make independent determinations of suitability and completeness of information from all sources to ensure their proper use.

Legend:

AICS	Australian Inventory of Chemical Substances.
APVMA	Australian Pesticides and Veterinary Medicines Authority.
CAS No.	Chemical Abstracts Service Registry Number.
GHS	Globally Harmonized System of Classification and Labelling of Chemicals.
Hazchem Code	Emergency action code of numbers and letters that provide information to emergency
LD₅₀	The median lethal dose, being a statistically derived single dose of a substance that can be expected to cause death in 50% of animals.
NICNAS	National Industrial Chemicals Notification and Assessment Scheme.
PPE	Personal Protective Equipment.
PVC	Polyvinyl chloride.
SDS	Safety Data Sheet.
STOT	Specific Target Organ Toxicity.
SWA	Safe Work Australia.

References:

ChemID Plus
Chemwatch
EPA New Zealand Chemical Classification and Information Database (CCID)



SAFETY DATA SHEET

Title: JURAMATE INJECTION		Document: SDS-AU043	
		Rev: 3.1	PAGE 8 OF 8
Status: Current	Issue Date: 20-Feb-2023	Effective Date: 01-Mar-2023	Review Date: 17-Jan-2028

Revision History:

Date of Revision	Reason
11 February 2016	Classification of substance to GHS classification and update of SDS to comply with SWA Code of Practice.
30 July 2018	Updated section 1 (email address) and section 2 to classify substance as specific target organ toxicity (SE) Category 1 rather than RE. Sections 7 and 11 also updated to reflect this change.
19 December 2022	Routine 5-year review. Update to GHS 7. Updates to all sections including update to GHS classification.
16 January 2023	Addition of Juramate P Prostaglandin Injection for Pigs to the SDS.
01 March 2023	Update of Customer Service and emergency telephone numbers to Zoetis numbers.

END OF SDS